| DrugRepV_3934 | IHVR-19029 | NA | NA | Ebola virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 29253498 |
| DrugRepV_4006 | 2-APB | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4007 | A23187 | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4008 | Di-Tert-Butylhydroquinone | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4009 | CA1001 | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4010 | Dantrolene | Musculo-Skeletal System | Malignant hyperthermia | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4011 | Ionomycin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4012 | Ryanodine | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4013 | Thapsigargin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4014 | Xestospongin C | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4015 | 2-APB | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4016 | A23187 | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4017 | Di-Tert-Butylhydroquinone | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4018 | CA1001 | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4019 | Dantrolene | Musculo-Skeletal System | Malignant hyperthermia | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4020 | Ionomycin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4021 | Ryanodine | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4022 | Thapsigargin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4023 | Xestospongin C | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4024 | Agatoxin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4025 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4026 | Conotoxin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4027 | Gabapentin | NERVOUS SYSTEM | Epilepsy (seizure) | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4028 | Lanthanum Chloride | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4029 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational, Withdrawn | 20668647 |
| DrugRepV_4030 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4031 | Praziquantel | Antiparasitic products, Insectisides and Repellents | Schistosomiasis | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4032 | Tetrandrine | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental | 20668647 |
| DrugRepV_4033 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4034 | 5-N-ethyl isopropyl amiloride | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4035 | Amiloride | Cardiovascular agents | Hypertension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4036 | Benzamil | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4037 | Monensin | Antibiotics | Bacterial infections | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental, Vet approved | 20668647 |
| DrugRepV_4038 | Phenytoin | Nervous System | Seizures | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Vet approved | 20668647 |
| DrugRepV_4039 | Agatoxin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4040 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4041 | Conotoxin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4042 | Gabapentin | Epilepsy | Epilepsy (seizure) | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4043 | Lanthanum Chloride | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4044 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational, Withdrawn | 20668647 |
| DrugRepV_4045 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4046 | Praziquantel | Antiparasitic products, Insectisides and Repellents | Schistosomiasis | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4047 | Tetrandrine | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental | 20668647 |
| DrugRepV_4048 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4049 | 5-N-ethyl isopropyl amiloride | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4050 | Amiloride | Cardiovascular agents | Hypertension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4051 | Benzamil | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4052 | Monensin | Antibiotics | Bacterial infections | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental, Vet approved | 20668647 |
| DrugRepV_4053 | Phenytoin | Nervous System | Seizures | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Vet approved | 20668647 |
| DrugRepV_4054 | 7-octyl-indolactam | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4055 | Cyclosporine | Antineoplastic and Immunomodulating Agents | Immune disorders | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4056 | Gliotoxin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4057 | Oleic Acid | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4058 | Phenoxybenzamine | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4059 | PKC Inhibitor | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4060 | PMA | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4061 | Rottlerin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4062 | U73122 | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4063 | 7-octyl-indolactam | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4064 | Cyclosporine | Immune disorders | Immune disorders | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4065 | Gliotoxin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4066 | Oleic Acid | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4067 | Phenoxybenzamine | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4068 | PKC Inhibitor | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4069 | PMA | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4070 | Rottlerin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4071 | U73122 | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4072 | 25-OH-cholecalciferol | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Nutraceutical | 20668647 |
| DrugRepV_4073 | 4-OH-tamoxifen | NA | Breast cancer | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4074 | Arg-vasopressin | NA | Enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4075 | Bradykinin | NA | Hypertension and Diabetes Type 2 | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4076 | Caffeine | Nervous System | Fatigue, orthostatic hypotension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4077 | Cholecalciferol | NA | Vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4078 | Clotrimazole | Dermatologicals | Fungal infections | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4079 | Propranolol | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational | 20668647 |
| DrugRepV_4080 | 25-OH-cholecalciferol | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Nutraceutical | 20668647 |
| DrugRepV_4081 | 4-OH-tamoxifen | NA | Breast cancer | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4082 | Arg-vasopressin | NA | Enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4083 | Bradykinin | NA | Hypertension and Diabetes Type 3 | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4084 | Caffeine | Nervous System | Fatigue, orthostatic hypotension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4085 | Cholecalciferol | NA | Vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4086 | Clotrimazole | Dermatologicals | Fungal infections | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4087 | Propranolol | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational | 20668647 |